14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
FBRX vs BOLD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FBRX vs BOLD. Trailing 12-month operating profitability (FBRX 0.0% vs BOLD 0.0%) and valuation multiples (FBRX N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FBRX vs BOLD Key Questions & Quantitative Answers
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FBRX leads the Growth & Scale pillar: FBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FBRX generates N/A in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, FBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.
FBRX and BOLD trade at balanced relative valuation multiples. FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBRX (-62.3% ROE) versus BOLD (-64.6% ROE) capital efficiency.
In options market volatility and institutional positioning, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.